[Financial interests characterize published reports on coxiber. Whom can we rely on?].
Håkansson
Jan
J
jan.hakansson@jll.se
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001168:Arthritis / Q000188:drug therapy; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D000068579:Celecoxib; D016265:Conflict of Interest; D018849:Controlled Clinical Trials as Topic; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D004345:Drug Industry / Q000191:economics; D006801:Humans; D007783:Lactones / Q000009:adverse effects / Q000627:therapeutic use; D010506:Periodicals as Topic; D017594:Publication Bias; D011643:Publishing; D011720:Pyrazoles; D016032:Randomized Controlled Trials as Topic; D012109:Research Support as Topic / Q000191:economics; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use; D013450:Sulfones
D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D000068579:Celecoxib